Tp12-dependent IFN-g production: contribution to host defense and autoimmunity
Tp12 依赖性 IFN-g 产生:对宿主防御和自身免疫的贡献
基本信息
- 批准号:8121441
- 负责人:
- 金额:$ 16.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntigen PresentationAreaAutoimmune DiseasesAutoimmunityB-LymphocytesBacterial InfectionsBiochemicalBiochemical PathwayBiologicalBiological AssayCD4 Positive T LymphocytesCell Differentiation processCell secretionCellsCellular ImmunityCollaborationsCommunicable DiseasesCytokine ReceptorsDataDefectDevelopmentDiabetes MellitusDiseaseDrug DesignEffector CellEventGene ExpressionGenesGenetic TranscriptionGoalsHomeostasisHost DefenseHumanImmune responseImmunityImmunoblottingImmunoglobulin Class SwitchingInfectionInflammatoryInflammatory Bowel DiseasesInterferon InducersInterferon Type IIInterferonsInterleukin-12InterventionKnockout MiceKnowledgeLinkLymphoidMAP3K8 geneMediatingMemoryMessenger RNAMolecularMolecular BiologyMusNatural ImmunityNatural Killer CellsPathologicPathway interactionsPhosphotransferasesPlayPredispositionProcessProductionProteinsRegulationResearchResearch PersonnelResistance to infectionRheumatoid ArthritisRoleSignal PathwaySignal TransductionSignaling MoleculeT-LymphocyteT-Lymphocyte SubsetsTechniquesTestingTh1 CellsTherapeutic InterventionVirus DiseasesWorkadaptive immunitybactericidebasecell typecytokinecytotoxicdefined contributioninfectious disease modelinsightkinase inhibitormacrophagenovelprogramsresponsetreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Cytokines mediate virtually every facet of immunity including lymphoid development, homeostasis, differentiation, tolerance and memory. Interleukin (IL)-12 production during infection determines the type and duration of adaptive immune response through the induction of the pro-inflammatory cytokine, interferon(IFN)-gamma. Defects in signaling via IL-12/IFN-gamma are associated with susceptibility to infections. Of equal concern is that dysregulation of IL-12/IFN-gamma is associated with the development of autoimmunity. Therefore, a comprehensive understanding of the IL-12 signaling pathway is crucial for the development of novel treatment strategies. Currently, our knowledge of IL-12 signaling intermediates is quite incomplete. In an attempt to gain insight into the molecular basis of IL-12's action we identified the serinethreonine kinase, Tpl2, as an IL-12-inducible gene. Because of its function as a kinase, we hypothesize that Tpl2 is a critical intermediate in IL-12 signaling per se that is required for IFN-gamma production, resistance to infection, and, in pathologic settings, the development of autoimmune disease. In order to broaden our understanding of the molecular biology of Tpl2 as it relates to IL-12-mediated IFN-gamma production we propose (1) to define the biochemical pathway that links Tpl2 to IL-12 signaling and (2) to characterize the role of Tpl2 in IFN-gamma production by T and NK cells and its contribution to host defense and the development of autoimmunity. Preliminary data confirm that Tpl2 is regulated by IL-12 in both T and NK cells and is required for the production of IFN-gamma by T cells. We will use standard biochemical techniques including immunoblotting and kinase assay to dissect the signaling role of Tpl2. We will further test our hypotheses by observing the immune responses of Tpl2-deficient mice in murine models of infectious disease and autoimmunity. Due to its causative role in autoimmunity, blockade of IL-12 signaling would be an attractive means for intervention. Because kinases have been implicated in the development of inflammatory diseases, the modulation of kinase activity has become an active area of research in new drug design. If the proposed work demonstrates that Tpl2 is critical in the development of autoimmune disease through the regulation of IL-12-induced production of IFN-gamma, then it will provide a rationale for the development of a Tpl2 selective kinase inhibitor for use in the treatment of human autoimmune diseases.
描述(由申请人提供):细胞因子介导免疫的几乎所有方面,包括淋巴发育、稳态、分化、耐受和记忆。感染期间白细胞介素(IL)-12的产生通过诱导促炎细胞因子干扰素(IFN)-γ来决定适应性免疫应答的类型和持续时间。通过IL-12/IFN-γ的信号传导缺陷与感染易感性相关。同样值得关注的是,IL-12/IFN-γ的失调与自身免疫的发展有关。因此,全面了解IL-12信号通路对于开发新型治疗策略至关重要。目前,我们对IL-12信号传导中间体的了解还相当不完整。为了深入了解IL-12作用的分子基础,我们鉴定了丝氨酸苏氨酸激酶Tp 12作为IL-12诱导基因。由于其作为激酶的功能,我们假设Tp 12是IL-12信号传导本身的关键中间体,其是IFN-γ产生、抗感染和在病理环境中自身免疫性疾病发展所需的。为了拓宽我们对Tp 12的分子生物学的理解,因为它涉及IL-12介导的IFN-γ产生,我们提出(1)定义将Tp 12与IL-12信号传导联系起来的生物化学途径和(2)表征Tp 12在T和NK细胞产生IFN-γ中的作用及其对宿主防御和自身免疫发展的贡献。初步数据证实,Tpl 2在T细胞和NK细胞中均受IL-12调节,并且是T细胞产生IFN-γ所需的。我们将使用标准生物化学技术,包括免疫印迹和激酶测定来剖析Tp 12的信号传导作用。我们将通过观察感染性疾病和自身免疫的鼠模型中Tp 12缺陷型小鼠的免疫应答来进一步测试我们的假设。由于其在自身免疫中的致病作用,IL-12信号传导的阻断将是一种有吸引力的干预手段。由于激酶与炎症性疾病的发展有关,因此激酶活性的调节已成为新药设计中的一个活跃的研究领域。如果所提出的工作证明Tpl 2通过调节IL-12诱导的IFN-γ的产生在自身免疫性疾病的发展中是关键的,那么它将为开发用于治疗人类自身免疫性疾病的Tpl 2选择性激酶抑制剂提供理论基础。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Signal transduction and Th17 cell differentiation.
- DOI:10.1016/j.micinf.2009.04.007
- 发表时间:2009-04
- 期刊:
- 影响因子:5.8
- 作者:O'Shea JJ;Steward-Tharp SM;Laurence A;Watford WT;Wei L;Adamson AS;Fan S
- 通讯作者:Fan S
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis.
- DOI:10.1016/j.immuni.2010.05.003
- 发表时间:2010-05-28
- 期刊:
- 影响因子:32.4
- 作者:Durant L;Watford WT;Ramos HL;Laurence A;Vahedi G;Wei L;Takahashi H;Sun HW;Kanno Y;Powrie F;O'Shea JJ
- 通讯作者:O'Shea JJ
Tumor Progression Locus 2 Promotes Induction of IFNλ, Interferon Stimulated Genes and Antigen-Specific CD8+ T Cell Responses and Protects against Influenza Virus.
- DOI:10.1371/journal.ppat.1005038
- 发表时间:2015-08
- 期刊:
- 影响因子:6.7
- 作者:Kuriakose T;Tripp RA;Watford WT
- 通讯作者:Watford WT
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wendy T Watford其他文献
The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-γ-induced cell death
免疫相关 GTP 酶 Irgm1 通过防止干扰素-γ诱导的细胞死亡来促进活化 CD4+T 细胞群体的扩增
- DOI:
10.1038/ni.1653 - 发表时间:
2008-09-21 - 期刊:
- 影响因子:27.600
- 作者:
Carl G Feng;Lixin Zheng;Dragana Jankovic;André Báfica;Jennifer L Cannons;Wendy T Watford;Damien Chaussabel;Sara Hieny;Patricia Caspar;Pamela L Schwartzberg;Michael J Lenardo;Alan Sher - 通讯作者:
Alan Sher
Interleukin-22: a sheep in wolf's clothing
白细胞介素-22:披着羊皮的狼
- DOI:
10.1038/nm0308-247 - 发表时间:
2008-03-01 - 期刊:
- 影响因子:50.000
- 作者:
Arian Laurence;John J O'Shea;Wendy T Watford - 通讯作者:
Wendy T Watford
Wendy T Watford的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wendy T Watford', 18)}}的其他基金
Tpl2 regulation of pDC function and SLE pathogenesis
Tpl2 对 pDC 功能和 SLE 发病机制的调节
- 批准号:
10242226 - 财政年份:2020
- 资助金额:
$ 16.2万 - 项目类别:
Tpl2 regulation of pDC function and SLE pathogenesis
Tpl2 对 pDC 功能和 SLE 发病机制的调节
- 批准号:
10064466 - 财政年份:2020
- 资助金额:
$ 16.2万 - 项目类别:
Regulation of mucosal immunity to respiratory viruses by Tpl2
Tpl2对呼吸道病毒粘膜免疫的调节
- 批准号:
9809582 - 财政年份:2019
- 资助金额:
$ 16.2万 - 项目类别:
Regulation of mucosal immunity to respiratory viruses by Tpl2
Tpl2对呼吸道病毒粘膜免疫的调节
- 批准号:
9926820 - 财政年份:2019
- 资助金额:
$ 16.2万 - 项目类别:
MAP3K8-mediated regulation of adaptive immune responses and autoimmunity
MAP3K8 介导的适应性免疫反应和自身免疫的调节
- 批准号:
8439506 - 财政年份:2012
- 资助金额:
$ 16.2万 - 项目类别:
MAP3K8-mediated regulation of adaptive immune responses and autoimmunity
MAP3K8 介导的适应性免疫反应和自身免疫的调节
- 批准号:
8535939 - 财政年份:2012
- 资助金额:
$ 16.2万 - 项目类别:
MAP3K8-mediated regulation of adaptive immune responses and autoimmunity
MAP3K8 介导的适应性免疫反应和自身免疫的调节
- 批准号:
9181374 - 财政年份:2012
- 资助金额:
$ 16.2万 - 项目类别:
MAP3K8-mediated regulation of adaptive immune responses and autoimmunity
MAP3K8 介导的适应性免疫反应和自身免疫的调节
- 批准号:
8586250 - 财政年份:2012
- 资助金额:
$ 16.2万 - 项目类别:
Tp12-dependent IFN-g production: contribution to host defense and autoimmunity
Tp12 依赖性 IFN-g 产生:对宿主防御和自身免疫的贡献
- 批准号:
7901083 - 财政年份:2009
- 资助金额:
$ 16.2万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 16.2万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 16.2万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 16.2万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 16.2万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 16.2万 - 项目类别: